ArticleHepatology communications2019
A Behavioral Health Program for Alcohol Use Disorder, Substance Abuse, and Depression in Chronic Liver Disease.
Article in Hepatology communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Integrated approaches to reduce alcohol use in people with liver disease: a scoping review and quantitative analysis.Alcohol and alcoholism (Oxford, Oxfordshire) · 2025Article
- The Role of Patient-Reported Outcomes in Cirrhosis.The American journal of gastroenterology · 2025Review
- Trends in hospital admissions and mortality among inflammatory bowel disease patients with substance use disorder: a 10-year United States nationwide analysis.Proceedings (Baylor University. Medical Center) · 2023Article
- Treatment of substance use disorders in patients with chronic liver disease.Clinical liver disease · 2022Review
- Assessment of mental health in patients with chronic liver disease.Clinical liver disease · 2022Review
- Psychiatric Disorders and Their Treatment: Impact of Outcomes in Patients With Chronic Liver Disease.Clinical liver disease · 2022Review
- Multimodal multidisciplinary management of alcohol use disorder in liver transplant candidates and recipients.Translational gastroenterology and hepatology · 2022Review
- The Impact of Social Workers in Cirrhosis Care: a Systematic Review.Current treatment options in gastroenterology · 2022Review
- Contemporary Trends in Hospitalizations for Comorbid Chronic Liver Disease and Substance Use Disorders.Clinical and translational gastroenterology · 2021Article
- Which patient should be prioritized for liver transplant: NAFLD?Clinical liver diseaseReview
- The role of patient-reported outcomes in a patient-centered care model for managing chronic liver diseases.Clinical liver diseaseArticle
- Management of Alcohol Use Disorder in Patients With Alcoholic Liver Disease.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alcohol use disorder, substance abuse, and depression are illnesses that deteriorate the quality of life (QOL) of patients with chronic liver disease (CLD). Screening and behavioral health programs integrated into routine practice can mitigate the deleterious effects of such illnesses but have not been adopted in hepatology practices. We implemented a behavioral health program based on the Screening, Brief Intervention, and Referral to Treatment (SBIRT) model and assessed its acceptability and effectiveness in improving QOL. This was a quality improvement study. Patients with CLD and a scheduled outpatient visit in the hepatology clinic were screened while waiting for their appointment. All patients who screened positive for any of the three illnesses were offered a brief intervention (BI) at the point of care and at 3 months by a trained social worker. The BI used the principles of motivational interviewing and cognitive behavioral therapy. Severity of illness was assessed at baseline, 3 months, and 6 months. Participants completed an acceptability survey at 6 months. We screened 303 patients; 61.7% were positive for any of the three illnesses assessed. Among the positive patients, depression was most common (48.4%), alcohol and substance abuse were each 26%. For the 95 patients who underwent BI, QOL improved from baseline to 3 and 6 months (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.